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Available online 21 February 2018Huntington's disease (HD) is an incurable, autosomal dominant, hereditary neurodegenerative disorder that typ-
ically manifests itself inmidlife. This pathology is linked to the deregulation ofmultiple, as yet unknown, cellular
processes starting before HD onset. A human iPS cell line was generated from skin fibroblasts of a subject at the
presymptomatic life stage, carrying a polyglutamine expansion in HTT gene codifying Huntingtin protein. The
iPSC line contained the expected CAG expansion, expressed the expected pluripotency markers, displayed in
vivo differentiation potential to the three germ layers and had a normal karyotype.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).(continued)
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HD is a completely penetrant genetic disorder, thus the possibility of
studying an iPSC line obtained when patient has no evident symptoms
of the disease will theoretically allow us to interpret how the patholog-
ical process may develop in vitro before clinical manifestations appear,
in a pathophysiological human context.
Resource details
Huntington's disease (HD) is a dominantly inherited neurodegener-
ative disease caused by a polyglutamine expansion in the N-terminus of
the huntingtin protein (HTT). Individuals with 35 CAG repeats or fewer
are not affected, while those with 36 and more CAG repeats willthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal iPSCs morphology 1A
Phenotype Qualitative analysis Expression of pluripotency markers: Oct4, Tra1-60 1B
Quantitative analysis Expression of pluripotency markers: OCT4, LIN28, L-MYC, KLF4, SOX2
Silenced transgene expression (from episomes): OCT4, LIN28,
L-MYC, KLF4, SOX2
1D
1C
Genotype Karyotype (G-banding)
and resolution
Normal Karyotype: 46 XX, resolution: 450–500 1G
Identity STR analysis 19 sites tested: all matched Data available from the authors
Mutation analysis (IF APPLICABLE) Sequencing PCR results:
17 ± 1 and 43 ± 2 CAG repeats in fibroblasts
17 ± 1 and 43 ± 2 CAG repeats in IPS cell line.
1H
Microbiology and virology Mycoplasma Mycoplasma tested: negative Supplementary Fig. 1
Differentiation potential Embryoid body formation
and Teratoma formation
Expression of genes of the three germ layers in embryoid
bodies: NESTIN, PAX6, SOX1, FOXA2, GATA4, SOX17, EOMES and T.
Teratoma: formation of three germ layers.
1E
1F
Table 2
Reagents details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and
RRID
Pluripotency
Markers
Rabbit anti-OCT4
Mouse anti-TRA-1-60
1:100
1:100
Life Technologies
(A13998)
Life Technologies (411000)
Secondary
antibodies
anti-Rabbit AlexaFluor 488
anti-Mouse AlexaFluor
555
1:10000
1:10000
Invitrogen (A11034)
Invitrogen (A21422)
Primers
Target Forward/reverse primer (5′–3′)
Episomal genes eOCT4 Fwd: CAT TCA AAC TGA GGT AAG GG
Rev.: TAG CGT AAA AGG AGC AAC ATA G
eKLF4 Fwd: CCA CCT CGC CTT ACA CAT GAA GA
Rev.: TAG CGT AAA AGG AGC AAC ATA G
eLIN28 Fwd: AGC CAT ATG GTA GCC TCA TGT CCG C
Rev.: TAG CGT AAA AGG AGC AAC ATA G
eL-MYC Fwd: GGC TGA GAA GAG GAT GGC TAC
Rev.: TTT GTT TGA CAG GAG CGA CAA T
eSOX2 Fwd: TTC ACA TGT CCC AGC ACT ACC AGA
Rev.: TTT GTT TGA CAG GAG CGA CAA T
Pluripotency genes OCT4 Fwd: CCC CAG GGC CCC ATT TTG GTA CC
Rev.: ACC TCA GTT TGA ATG CAT GGG AGA GC
KLF4 Fwd: ACC CAT CCT TCC TGC CCG ATC AGA
Rev.: TTG GTA ATG GAG CGG CGG GAC TTG
LIN28 Fwd: AGC CAT ATG GTA GCC TCA TGT CCG C
Rev.: TCA ATT CTG TGC CTC CGG GAG CAG
GGT AGG
L-MYC Fwd: GCG AAC CCA AGA CCC AGG CCT GCT CC
Rev.: CAG GGG GTC TGC TCG CAC CGT GAT G
SOX2 Fwd: TTC ACA TGT CCC AGC ACT ACC AGA
Rev.: TCA CAT GTG TGA GAG GGG CAG TGT GC
18S Fwd: GGC CCT GTA ATT GGA ATG AGT C
Rev.: CCA AGA TCC AAC TAC GAG CTT
Differentiation Markers SOX1 Hs01057642_s1
NESTIN Hs04187831_g1
PAX6 Hs00240871_m1
EOMES Hs00172872_m1
T Hs00610080_m1
GATA4 Hs00171403_m1
FOXA2 Hs00232764_m1
SOX17 Hs01057642_s1
18S Hs03003631_g1
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2017). TheHDmutation is fully penetrantwith the time of onset correlat-
ing to the number of repeats. Skin fibroblasts were obtained from a pa-
tient carrying 43 CAG repeats. This 28-year-old patient was still
presymptomatic at the time of the skin biopsy, showing a Diagnostic Con-
fidence Level (DCL)=0. Skinfibroblastswere reprogrammed into plurip-
otent stem cells through the nucleofection of episomal vectors containing
theYamanaka factors: OCT4, KLF4, L-MYC, SOX2, LIN28 and sh-p53 (Okita
et al. 2011). The established CSSi004-A (2962) iPSC line showed typical
human stem cell-like morphology in phase contrast microscopy (Fig.
1A). These iPSC-like colonies were maintained by mechanical splitting
in Matrigel coated wells in iPSC media, NutristemXF. Pluripotency of
CSSi004-A (2962) line was confirmed by the expression of the transcrip-
tion factor OCT4 aswell as by the expression of the surfacemarker TRA-1-
60 obtained through immunofluorescence analysis (Fig. 1B, Table 1). Epi-
somal plasmids are non-integrative, so they are gradually lost from the
cells after rapid cell divisions: after 8 passages, the colonies were free of
transgene expression. The RNA from an aliquot of the nucleofected fibro-
blasts was used as a control of transgene expression (Fig. 1C). A quantita-
tive real-timePCR (qPCR)was used toquantifymRNAexpression levels of
pluripotent markers in the CSSi004-A (2962) cell line; all five genes, in-
cluding OCT4, KLF4, LIN28, L-MYC and SOX2 showed high levels of ex-
pression in the iPSC line, whereas there was a very low expression in
the parental fibroblasts used as controls (Fig. 1D). The CSSi004-A (2962)
formed embryoid bodies which spontaneously differentiated into three
germ layers; the results were analyzed by qPCR. Ectodermal lineage was
confirmed by overexpression of SOX1,NESTIN and PAX6,while themeso-
dermal lineage was determined through expressions of BRACHIURY (T)
and EOMES. Overexpression of GATA4, FOXA2 and SOX17 confirmed
the differentiation of the endoderm layer. qPCR reactions were normal-
ized against internal controls (18S) and plotted relative to expression
levels of the iPSC (Fig. 1E). Differentiation capacity into three germ layers
was also demonstrated by in vivo teratoma formation (Fig. 1F). Authenti-
cation of the CSSi004-A (2962) cell line was verified using short tandem
repeats analysis andwas identical to the parental cell line (STR data avail-
able with the authors). Karyotype analysis demonstrated no gain or loss
of chromosomes, and no subkaryotypic aberrations (known to be recur-
rent in human pluripotent stem cells) were detected (Fig. 1G). The allele
sizes (17± 2 and 43± 2 CAG repeats) in fibroblast and IPS cell line were
the same (Fig. 1H).
Materials and methods
Skin biopsy and fibroblast reprogramming
The skin biopsy was mechanically dissected and cultured in fibro-
blast medium (DMEM high glucose, 20% FBS, 2 mM L-glutamine and
1% penicillin–streptomycin (all reagents from Sigma Aldrich)) for30 days at 37 °C and 5% CO2 to allow fibroblasts to grow out. Briefly, 1
× 105 fibroblasts were nucleofected with 3 μg 1:1:1mix of the episomal
plasmids pCXLE-hUL (Addgene #27080), pCXLE-hSK (Addgene
#27078) and pCXLE-hOCT4-shp53 (Addgene #27077). The
nucleofected cells were plated in fibroblast medium for one week. On
day 7 the cells were counted and plated on Matrigel (1:100) (BD
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dium (Biological Industries). When iPSC colonies reached a sufficient
size, they were manually cut and passaged for expansion. Absence of
mycoplasma contamination was verified by PCR analysis using EZ-PCR
kit (Biological Industries).
Immunofluorescence staining
Cellswere fixed using 4% paraformaldehyde for 20min at room tem-
perature. The cells were incubated with Blocking Buffer (PBS, 20% Nor-
mal Goat Serum, 0.1% Triton X-100) for 30 min at room temperature.
Next, primary antibodies diluted in blocking buffer were incubated
overnight at 4 °C. After washing, Alexa Fluor 594- and/or Alexa Fluor
488-conjugated secondary antibodies in PBS 1× were added 1 h at
room temperature. Nuclei were counterstained with DAPI. Micrographs
were taken using a Nikon C2 fluorescencemicroscope and NIS Elements
1.49 software.
Real-time PCR analysis
Total RNAwas isolated from cultured cells with Trizol (Life Technol-
ogies). Reverse transcription of 1 μg of RNA was performed using High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) after di-
gestion with DNAse I (Life Technologies). Each RNA sample was tested
in duplicate; 18S was used to normalize transcript abundance and cal-
culations were performedwith the delta Ct method. Statistical analyses
were performed on three independent experiments. Primers are listed
in Table 2.
In vitro spontaneous differentiation
The cell clumps from iPS were plated on Petri dishes in NutristemXF
medium. One day later, NutristemXFmediumwas substituted with dif-
ferentiation medium: DMEM/F12, 20% KSR (Gibco), 0,1 mM NEAA,
0.1 mM β-mercaptoethanol, 1% Pen/Strep. The embryoid bodies (EBs)
were grown for two weeks.
Karyotyping
iPSCs were cultured in chamber slides (Thermo Fisher Scientific)
coated with Matrigel in NutristemXF medium for 2–3 days. Cells were
treated with a 0.1 μg/mL COLCEMID solution (Thermo Fisher Scientific)for 60min at 37 °C. Metaphases were obtained by adding 30mMKCl in
10%FBS at 37 °C for 6 min and by fixation, using a cold fresh-made 3:1
ethanol:acetic acid solution. Karyotype analysis was carried out on
GTG-banded metaphases (450–500 resolution). Fifteen metaphases
were counted and three karyotypes analyzed. Only clonal aberrations
were considered, following ISCN recommendations.
STR analysis
Fibroblasts and iPSCs DNAwas extracted by Dneasy blood and tissue
kit (QIAGEN). PCR amplification of 19 distinct STRs (D13S252, D13S305,
D13S634, D13S800, D13S628, D18S819, D18S535, D18S978, D18S386,
D18S390, D21S11, D21S1437, D21S1409, D21S1442, D21S1435,
D21S1446, DXS6803, XHPRT, DXS1187) was carried out using the
QST*Rplusv2 kit (Elucigene Diagnostics), PCR products were separated
on anABI Prism3130DNAsequencer and analyzed byGeneMapper ver-
sion 4.0 (Applied Biosystems).
Teratoma formation
Approximately 3 × 106 dispase-treated iPSCs, in 100 μL of Matrigel,
were injected into the right flank of nude mice, following ethical guide-
lines. About 4–6 weeks after injection, tumors were dissected, fixed in
10% formalin (Sigma Aldrich), paraffin-embedded, sectioned and
stained with hematoxylin/eosin. The presence of differentiated tissues
representative of the three embryonic germ layers was analyzed.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.scr.2018.02.014.
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